Welcome to our dedicated page for IDRA news (Ticker: IDRA), a resource for investors and traders seeking the latest updates and insights on IDRA stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect IDRA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of IDRA's position in the market.
Idera Pharmaceuticals (Nasdaq: IDRA) has initiated a private placement with institutional investors, raising $5.1 million through the sale of common stock and warrants. The purchase price per share is $1.845, with warrants exercisable at $2.58. Investors have the option for a second tranche of $5.1 million, contingent on the announcement of data from the ILLUMINATE-301 trial, with a purchase price of $6.50 per share and warrants at $9.75. The proceeds will support the clinical development of tilsotolimod and general corporate purposes.
Idera Pharmaceuticals (Nasdaq: IDRA) announced preliminary data from ILLUMINATE-206, a Phase 2 study evaluating tilsotolimod combined with Opdivo® and Yervoy® for MSS-CRC patients. The initial cohort of 10 patients exhibited a generally well-tolerated safety profile; no treatment discontinuations occurred due to adverse events. One patient showed stable disease, while nine progressed. Idera plans to enhance the trial design and expand patient enrollment, targeting the next cohort's start in Q4 2020 and data release in Q2 2021.
FAQ
What is the market cap of IDRA (IDRA)?
